Pooled overall survival (OS) analysis with expanded access protocol (EAP) data. Individual patient survival data were pooled from 1,861 patients with metastatic melanoma from 12 clinical investigations of ipilimumab and 2,985 patients with metastatic melanoma from a US EAP (n = 4,846). Median OS was 9.5 months (95% CI, 9.0 to 10.0 months) with a 3-year survival rate of 21% (95% CI, 20% to 22%). Crosses indicate censored patients.